4th Quarter - Report

BROWNSTEIN HYATT FARBER SCHRECK, LLP for NOVARTIS

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to cell and gene therapy Pharmaceutical pricing Issues related to the development of therapies for rare diseases, Issues related to COVID-19 Issues related to reconciliation 340B Drug Discount Program Issues related to PDUFA and pharmaceutical IP H.R.5376 - Inflation Reduction Act of 2022 Issues related to pharmacy benefit managers (PBMs) H.R. 2617 Consolidated Appropriations Act, 2023 Supply chain issues affecting pharmaceutical products

LobbyistCovered position, as disclosed
LAURA JOHNSON BOLLIER —
NADEAM ELSHAMI —
EMILY FELDER —
MARC LAMPKIN —
BRIAN THOMAS MCGUIRE New Asst Sec. for Legis. Affairs, Treasury; Counselor, Treasury; COS, Sen McConnell; Acting Staff Dir, R Comm Center, Sen McConnell; Dep Com Dir, Sen McConnell; Chief Speechwriter, Sen McConnell; Chief Speechwriter, HUD
R. JAMES NICHOLSON —
ZACHARY PFISTER —
ADAM STEINMETZ —
BRIAN WILD —

Contacted: HOUSE OF REPRESENTATIVES

Bills named: H.R. 2617 (117th), H.R. 5376 (117th)

Veterans VET

Opportunities for health care collaboration Issues related to Medicare and Medicaid for Veterans

LobbyistCovered position, as disclosed
NADEAM ELSHAMI —
MARC LAMPKIN —
ZACHARY PFISTER —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.